Cetuximab and irinotecan in patients with colorectal cancer refractory to oxaliplatin and irinotecan

被引：0

作者：

Gonzalez-Baron, M. ^{[1
]}

Blanco, M. ^{[1
]}

Feliu, J. ^{[1
]}

Gomez, C. ^{[1
]}

Casado, E. ^{[1
]}

Castro, J. ^{[1
]}

Belda-Iniesta, C. ^{[1
]}

Garrido, M. ^{[1
]}

Aguayo, C. ^{[1
]}

Campos, M. A. ^{[1
]}

机构：

[1] Hosp La Paz, Madrid, Spain

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

14600

引用

页数：1

共 50 条

[41] Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer
Cao, SS
Bhattacharya, A
Durrani, FA
Fakih, M
EXPERT OPINION ON PHARMACOTHERAPY, 2006, 7 (06) : 687 - 703
[42] Becam: A salvage protocol with bevacizumab, capecitabin, and mitomycin C for patients with metastatic colorectal or gastric cancer refractory to 5-fluorouracil, oxaliplatin, irinotecan, and cetuximab
Peinert, SP
Grothe, WG
Kuehne, IK
Kegel, TK
Arnold, DA
Schmoll, HJS
ANNALS OF ONCOLOGY, 2006, 17
[43] Salvage therapy with bevacizumab, capecitabin, and mitomycin C (BECAM) for patients with metastatic colorectal or gastric cancer refractory to 5-fluorouracil, oxaliplatin, irinotecan, and cetuximab
Peinert, S.
Arnold, D.
Grothe, W.
Lesske, J.
Siewczynski, R.
Schaedlich, B.
Kegel, T.
Behrmann, C.
Schmoll, H.-J.
EJC SUPPLEMENTS, 2005, 3 (02): : 226 - 226
[44] The use of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer
Poston, GJ
EJSO, 2005, 31 (04): : 325 - 330
[45] Influence of comorbidity, age and performance status on treatment efficacy and safety of cetuximab plus irinotecan in irinotecan-refractory elderly patients with metastatic colorectal cancer
Jehn, C. F.
Boening, L.
Kroening, H.
Pezzutto, A.
Lueftner, D.
EUROPEAN JOURNAL OF CANCER, 2014, 50 (07) : 1269 - 1275
[46] Irinotecan, cetuximab, and bevacizumab (CBI) versus irinotecan, cetuximab, and placebo (CI) in irinotecan-refractory metastatic colorectal cancer (mCRC): Results from an ACCRU network randomized phase II trial
Lipsyc-Sharf, Marla
Ou, Fang-Shu
Yurgelun, Matthew B.
Rubinson, Douglas Adam
Schrag, Deborah
Dakhil, Shaker R.
Stella, Philip J.
Weckstein, Douglas Jay
Wender, Donald B.
Faggen, Meredith Gail
Zemla, Tyler
Heying, Erica N.
Schuetz, Samantha R.
Noble, Stephanie
Meyerhardt, Jeffrey A.
Bekaii-Saab, Tanios S.
Fuchs, Charles S.
Ng, Kimmie
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[47] EPIC:: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer
Sobrero, Alberto F.
Maurel, Joan
Fehrenbacher, Louis
Scheithauer, Werner
Abubakr, Yousif A.
Lutz, Manfred P.
Vega-Villegas, M. Eugenia
Eng, Cathy
Steinhauer, Ernst U.
Prausova, Jana
Lenz, Heinz-Josef
Borg, Christophe
Middleton, Gary
Kroening, Hendrik
Luppi, Gabriele
Kisker, Oliver
Zubel, Angela
Langer, Christiane
Kopit, Justin
Burris, Howard A., III
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (14) : 2311 - 2319
[48] Improved survival with combination oxaliplatin, irinotecan, cetuximab for metastatic pancreatic cancer
Lee, F.
Roach, M.
Duong, L.
Heywood, G.
Parasher, G.
Rasila, K.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[49] Phase II Trial of Cetuximab Plus Cisplatin and Irinotecan in Patients With Cisplatin and Irinotecan-refractory Metastatic Esophagogastric Cancer
Janjigian, Yelena Y.
Ku, Geoffrey Y.
Campbell, Jenny C.
Shah, Manish A.
Capanu, Marinela
Kelsen, David P.
Ilson, David H.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2014, 37 (02): : 126 - 130
[50] Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: The BOND-2 study
Saltz, Leonard B.
Lenz, Heinz-Josef
Kindler, Hedy L.
Hochster, Howard S.
Wadler, Scott
Hoff, Paulo M.
Kemeny, Nancy E.
Hollywood, Ellen M.
Gonen, Mithat
Quinones, Marcus
Morse, Meroe
Chen, Helen X.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (29) : 4557 - 4561

← 1 2 3 4 5 →